After agreeing this fall to participate in the Inflation Reduction Act (IRA) drug price negotiation program, AstraZeneca — whose type 2 diabetes therapy Farxiga (dapagliflozin) was among the first 10 drugs singled out for the new cost-cutting measure — is still fighting the government over the program.
Source: Drug Industry Daily